Indication

GLP-1 medications for Chronic weight management

GLP-1 medications for Chronic weight management, with sourced prices, shortage reports and study results.

Last updated

Last checked · Nov 16, 2026 UTC
4approved
8in development

Approved for this use

Alphabetical by active ingredient. Approved uses depend on the specific brand and formulation.

Liraglutide

Victoza, Saxenda

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk

Subcutaneous injection · Once daily

FDA shortage reportIn shortage (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

from $349/mo (healifynow.com/saxenda)

Saxenda via HealifyNow · HealifyNow

Checked on healifynow.com

Price conditions

its Saxenda page says "From $349/month" for Saxenda (liraglutide 3 mg, weight management), and "Your first consultation is free. No insurance needed, and you only pay if you start treatment." On the same page, "Can I cancel my Saxenda plan at any time?" is answered "Yes. There are no contracts, and you can cancel from your patient portal."

A starting price: the page does not say what the figure includes or how it changes with the dose; the page prices it per month with no contracts. Its pages also list "Liraglutide From $149/mo" without saying which kind of liraglutide it is. FDA-approved product.

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety

Orforglipron

Foundayo

FDA-approved for

  • Weight loss

Oral tablet (any time of day, no food or water restriction) · Once daily

FDA shortage report (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

$149/30 days (pharmacy.amazon.com/FOUNDAYO-0-8-MG-TABLET-Bottle-30-Tablet/dp/B0GVPY57CT)

Foundayo via Amazon Pharmacy · Amazon Pharmacy

Checked on pharmacy.amazon.com

Price conditions

without insurance, 0.8 mg; includes the manufacturer coupon if eligible (list price $648.90); prescription required

Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

30-day supply

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety

Semaglutide

Ozempic, Wegovy, Wegovy HD, Rybelsus

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk
  • Kidney
  • Liver

Subcutaneous injection (Ozempic, Wegovy); oral tablet (Rybelsus, oral Ozempic, Wegovy pill) · Once weekly (injectable); once daily (oral)

FDA shortage report (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

$149/30 days (pharmacy.amazon.com/Novo-Nordisk-Inc-WEGOVY-1-5-MG-TABLET-Bottle-30-Tablet/dp/B0GD6568YL)

Wegovy pill via Amazon Pharmacy · Amazon Pharmacy

Checked on pharmacy.amazon.com

Price conditions

without insurance, 1.5 mg; includes the manufacturer coupon if eligible (list price $1,348.80); prescription required

Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

30-day supply

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety

Tirzepatide

Mounjaro, Zepbound

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk
  • Sleep apnea

Subcutaneous injection · Once weekly

FDA shortage report (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

$299/28 days (pharmacy.amazon.com/ZEPBOUND-KWIKPEN-2-5-MG-DOSE-PEN-INJ/dp/B0GP27N9T3)

Zepbound KwikPen via Amazon Pharmacy · Amazon Pharmacy

Checked on pharmacy.amazon.com

Price conditions

without insurance, 2.5 mg; includes the manufacturer coupon if eligible (list price $498.98); prescription required

The 7.5 mg KwikPen is also $449. Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

28-day supply

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety
Word for word

What each FDA label says about chronic weight management

From the indications section of each manufacturer's current label. A brand's wording decides who it is approved for.

  • Foundayo: “FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.”FDA label, revised Jul 29, 2026 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
  • Saxenda: “SAXENDA is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in:”FDA label, revised Feb 25, 2026 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
  • Wegovy: “to reduce excess body weight and maintain weight reduction long term in: adults and pediatric patients aged 12 years and older with obesity; adults with overweight in the presence of at least one weight-related comorbid condition. to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition.”FDA label, revised Jun 18, 2026 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
  • Zepbound: “to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.”FDA label, revised Aug 28, 2026 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
From FDA and CMS records

Timing, generics and coverage

Read from each FDA label, FDA's Orange Book and CMS's Part D files, and updated when they change.

BrandSoonest top doseHalf-lifeGeneric approved?Patent on the medicine toOn Medicare Part D, 2025
Ozempic2 mg from week 13about 1 weekNot yet: tentative onlyDec 5, 20312,044,798
Wegovy7.2 mg from week 21about 1 weekNoDec 5, 2031108,843
Rybelsus14 mg from day 61about one weekNoMay 2, 2034280,455
Mounjaro15 mg from week 21about 5 daysNoJun 14, 20391,592,517
Zepbound15 mg from week 21about 5-6 daysNoMay 13, 2036160,298
Foundayo17.2 mg from day 151about 29 to 49 hoursNoSep 26, 2037None listed
Victoza1.8 mg from week 3about 13 hoursYes, 8None listed6,810
Saxenda3 mg from week 5about 13 hoursYes, 3None listedNone listed

How long each takes · Generics and patents · Who covers what

Investigational (pipeline)

Alphabetical by active ingredient. These entries are not FDA-approved for this category; open a record for the studied uses and evidence.

Amycretin

Amycretin (investigational)

Studied for

  • Weight loss
  • Type 2 diabetes

Subcutaneous injection and oral tablet (both in development) · Once weekly (injectable); once daily (oral)

Investigational. No FDA-approved purchase option.

Study evidence & development
GIP/GLP-1Phase 3

VK2735

VK2735 (investigational)

Studied for

  • Weight loss
  • Type 2 diabetes

Subcutaneous injection (oral tablet in development) · Once weekly (injectable); once daily (oral)

Investigational. No FDA-approved purchase option.

Study evidence & development
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.